Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Whole Genome Sequencing Solution Targets Unsolved Rare Disease Cases

By LabMedica International staff writers
Posted on 14 Oct 2026

Rare diseases often present persistent diagnostic challenges for patients and families. More...

Many patients undergo years of testing without receiving a diagnosis, and even comprehensive genetic testing can miss or fail to interpret disease-causing changes. A newly launched test solution now combines whole genome sequencing, RNA analysis, and ongoing reanalysis to support rare disease diagnosis.

Ambry Genetics (Aliso Viejo, CA, USA) has launched GenomeNext and GenomeReveal, a comprehensive whole genome sequencing (WGS) solution designed to help improve diagnosis of patients with rare diseases. GenomeNext analyzes a patient’s genome using a pangenome reference designed to better represent human genetic diversity. The approach is intended to improve variant detection across diverse ancestral backgrounds.

GenomeReveal adds integrated RNA analysis, which can provide additional evidence to help interpret certain DNA findings. The testing also includes Ambry’s Patient for Life program, through which laboratory-initiated proactive reanalysis re-evaluates patient data as gene-disease knowledge evolves. This reanalysis is designed to deliver clinically meaningful reclassifications to patients who previously received negative or uncertain results.

Published data cited by Ambry show that RNA analysis can significantly increase diagnostic yield. The cited research includes a 2024 JAMA Oncology study on diagnostic outcomes of concurrent DNA and RNA sequencing in individuals undergoing hereditary cancer testing. Ambry also cited a 2025 Genetics in Medicine study reporting that laboratory-driven proactive reanalysis led to positive reclassifications in 5% of initially negative or uncertain exome sequencing cases.

“Advances in the use of a pangenome reference representing wider human diversity, like RNA analysis, and ongoing reanalysis are not just technical upgrades. They lead to a more complete approach to clinical genomics that enables better variant detection, improves diagnostic yield across diverse populations and provides clinically meaningful insights that evolve over time. This is where the field is heading, toward more comprehensive, equitable and lifelong care for patients,” said Dr. Wendy Chung, Chief of the Department of Pediatrics at Boston Children’s Hospital and Mary Ellen Avery Professor of Pediatrics, Harvard Medical School.

Related Links:
Ambry Genetics
 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Slide Scanner System
NanoZoomer S540MD
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.